Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells

被引:14
作者
Kim, Hyangmi [1 ]
Kim, Minjung [1 ]
Lee, Junghun [1 ]
Yu, Hana [1 ]
Hah, Jung-Mi [1 ]
机构
[1] Hanyang Univ, Coll Pharm, Dept Pharm, Ansan Kyeonggi Do 426791, South Korea
基金
新加坡国家研究基金会;
关键词
Dihydropyrazolodiazepinone; Antiproliferative activity; Cancer cell line; Kinase inhibitor; Kinase selectivity; KINASE INHIBITORS; PATHWAY; BRAF; PI3K/PTEN/AKT/MTOR; RAS/RAF/MEK/ERK; DISCOVERY; MUTATIONS; LEUKEMIA; MELANOMA; TARGET;
D O I
10.1016/j.bmc.2011.09.042
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recently, we have reported the syntheses and antiproliferative activities of N-(5-amino-1-(4-methoxybenzyl)-1H-pyrazol-4-yl amide derivatives on melanoma cells. As a continuous work for antiproliferative agents in melanoma, here we report the synthesis of conformationally rigid analogs, phenyl-6,8-dihydropyrazolo[3,4-b][1,4] diazepin-7(1H)-one derivatives7a-g, 8a-o and their antiproliferative activities against A375P melanoma cell line and U937 hematopoietic cell line. Most compounds showed competitive antiproliferative activities to sorafenib, the reference standard. Among them, N-(3-(1-benzyl-7-oxo-1,6, 7,8-tetrahydropyrazolo[3,4-b][1,4]diazepin-5-yl)phenyl)-4-chloro-3-(trifluoro methyl)benzamide-amino1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-5-(3-(4-chloro-3-(trifluoromethyl) phenyl) ureido)-2-methylbenzamide (7b) exhibited potent activities (GI(50) = 0.43 mu M and 0.06 mu M) on both cell lines. It has been further confirmed to be a potent and selective Raf kinases inhibitor and also mild inhibitor of PI3K alpha. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6760 / 6767
页数:8
相关论文
共 20 条
[1]   Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health [J].
Chappell, William H. ;
Steelman, Linda S. ;
Long, Jacquelyn M. ;
Kempf, Ruth C. ;
Abrams, Stephen L. ;
Franklin, Richard A. ;
Baesecke, Joerg ;
Stivala, Franca ;
Donia, Marco ;
Fagone, Paolo ;
Malaponte, Graziella ;
Mazzarino, Maria C. ;
Nicoletti, Ferdinando ;
Libra, Massimo ;
Maksimovic-Ivanic, Danijela ;
Mijatovic, Sanja ;
Montalto, Giuseppe ;
Cervello, Melchiorre ;
Laidler, Piotr ;
Milella, Michele ;
Tafuri, Agostino ;
Bonati, Antonio ;
Evangelisti, Camilla ;
Cocco, Lucio ;
Martelli, Alberto M. ;
McCubrey, James A. .
ONCOTARGET, 2011, 2 (03) :135-164
[2]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[3]   In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling [J].
Dumaz, Nicolas ;
Hayward, Robert ;
Martin, Jan ;
Ogilvie, Lesley ;
Hedley, Douglas ;
Curtin, John A. ;
Bastian, Boris C. ;
Springer, Caroline ;
Marais, Richard .
CANCER RESEARCH, 2006, 66 (19) :9483-9491
[4]   A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma [J].
Fan, Qi-Wen ;
Knight, Zachary A. ;
Goldenberg, David D. ;
Yu, Wei ;
Mostov, Keith E. ;
Stokoe, David ;
Shokat, Kevan M. ;
Weiss, William A. .
CANCER CELL, 2006, 9 (05) :341-349
[5]   Exploiting the PI3K/AKT pathway for cancer drug discovery [J].
Hennessy, BT ;
Smith, DL ;
Ram, PT ;
Lu, YL ;
Mills, GB .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (12) :988-1004
[6]   Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells [J].
Kim, Mi-hyun ;
Kim, Minjung ;
Yu, Hana ;
Kim, Hwan ;
Yoo, Kyung Ho ;
Sim, Taebo ;
Hah, Jung-Mi .
BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (06) :1915-1923
[7]  
Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035
[8]   The discovery of potent cRaf1 kinase inhibitors [J].
Lackey, K ;
Cory, M ;
Davis, R ;
Frye, SV ;
Harris, PA ;
Hunter, RN ;
Jung, DK ;
McDonald, OB ;
McNutt, RW ;
Peel, MR ;
Rutkowske, RD ;
Veal, JM ;
Wood, ER .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (03) :223-226
[9]   A PROTEIN-KINASE INVOLVED IN THE REGULATION OF INFLAMMATORY CYTOKINE BIOSYNTHESIS [J].
LEE, JC ;
LAYDON, JT ;
MCDONNELL, PC ;
GALLAGHER, TF ;
KUMAR, S ;
GREEN, D ;
MCNULTY, D ;
BLUMENTHAL, MJ ;
HEYS, JR ;
LANDVATTER, SW ;
STRICKLER, JE ;
MCLAUGHLIN, MM ;
SIEMENS, IR ;
FISHER, SM ;
LIVI, GP ;
WHITE, JR ;
ADAMS, JL ;
YOUNG, PR .
NATURE, 1994, 372 (6508) :739-746
[10]   Rational design of inhibitors that bind to inactive kinase conformations [J].
Liu, Y ;
Gray, NS .
NATURE CHEMICAL BIOLOGY, 2006, 2 (07) :358-364